RCKT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Rocket Pharmaceuticals Inc (RCKT) is not a strong buy for a beginner, long-term investor at this time. Despite some positive catalysts like the FDA lifting the clinical hold and setting a PDUFA date for KRESLADI, the company's financial performance is weak, with declining net income and EPS. Additionally, technical indicators suggest the stock is overbought, and there is no strong trading signal from Intellectia Proprietary Trading Signals. Analysts have also lowered the price target, and the stock is expected to decline in the short term. Given the user's impatience and unwillingness to wait for optimal entry points, it is better to hold off on investing in this stock right now.
The MACD histogram is positive and expanding, indicating bullish momentum. However, the RSI is at 81.977, signaling the stock is overbought. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading near resistance levels (R1: 3.646, R2: 3.828). Overall, the technical indicators suggest caution.
FDA lifted the clinical hold on RP-A501, with plans to resume trials in H1
PDUFA action date set for March 28 for KRESLADI, which could lead to the company's first commercial launch.
Potential to receive a Rare Pediatric Disease Priority Review Voucher upon KRESLADI's approval.
Morgan Stanley lowered the price target from $7 to $5, maintaining an Equal Weight rating.
Weak financial performance with declining net income (-24.56% YoY) and EPS (-36.62% YoY).
Stock is overbought and expected to decline in the short term based on technical analysis and candlestick pattern trends.
In Q3 2025, Rocket Pharmaceuticals reported no revenue growth, with revenue at $0. Net income dropped by 24.56% YoY to -$50.33M, and EPS declined by 36.62% YoY to -0.45. Gross margin remained at 0%. Overall, the financials indicate weak performance.
Morgan Stanley recently lowered the price target from $7 to $5 while maintaining an Equal Weight rating. The firm expects small-to-mid cap biotech companies to outperform in 2026 but remains cautious on Rocket Pharmaceuticals.
